Key result
Measuring C-reactive protein alongside lipid levels improves the identification of women at risk for cardiovascular events.
Why the study?
Does the addition of C-reactive protein measurement to lipid screening improve the prediction of cardiovascular events in women?
Does the addition of C-reactive protein measurement to lipid screening improve the prediction of cardiovascular events in women?
Adding C-reactive protein measurement to standard lipid screening may improve cardiovascular risk prediction in women.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“A common teaching in cardiology holds that inflammation plays a causal role in atherosclerotic cardiovascular disease (ASCVD). The recent announcement that the ZEUS cardiovascular outcomes trial of the anti-inflammatory drug ziltivekimab returned null results has seriously challenged this.”
May enhance risk identification in women beyond lipids alone; leaves open prospective validation before any practice change.
The addition of the measurement of C-reactive protein to screening based on lipid levels may provide an improved method of identifying persons at risk for cardiovascular events.
Journal, society, and media accounts. Useful signal, not independent expert judgment.
No takes yet. Share an insight, caveat, or question.
Ridker et al. (2000) studied this question. Measuring C-reactive protein alongside lipid levels improves the identification of women at risk for cardiovascular events.
Synapse has enriched 10 related papers. Consider them for comparative context: